Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?
Autor: | Corrado Terranova, Alessia Aloisi, Andrea Miranda, Francesco Plotti, Stella Capriglione, Daniela Luvero, Roberto Angioli, Federica Guzzo, Roberto Montera, Patrizio Damiani |
---|---|
Rok vydání: | 2014 |
Předmět: |
Adult
Oncology medicine.medical_specialty endocrine system diseases medicine.medical_treatment Drug resistance Logistic regression Group A Biomarkers Pharmacological Group B WAP Four-Disulfide Core Domain Protein 2 Text mining Internal medicine Biomarkers Tumor Humans Medicine Aged Platinum Ovarian Neoplasms Chemotherapy business.industry Proteins General Medicine Middle Aged Prognosis medicine.disease female genital diseases and pregnancy complications Drug Resistance Neoplasm Response Evaluation Criteria in Solid Tumors CA-125 Antigen Female business Ovarian cancer |
Zdroj: | Tumor Biology. 35:7009-7015 |
ISSN: | 1423-0380 1010-4283 |
DOI: | 10.1007/s13277-014-1836-x |
Popis: | Actually, in literature there are not valid tools able to predict the chemotherapy response during first-line ovarian cancer treatment. CA125 and human epididymis protein 4 (HE4) levels of consecutive single-institution patients with epithelial ovarian cancer (EOC) were measured during first-line chemotherapy and until 6 months follow-up. First, patients were divided into two groups according to a temporal criterion: patients treated during 2009 (group A: training group) and patients treated during 2010 (group B: verification group). At sixth months follow-up, patients were sub-classified, within both groups, as platinum resistant or platinum sensitive/intermediate, according to Response Evaluation Criteria in Solid Tumors criteria, and the serum marker courses were further analyzed in each subgroup. Moreover, we performed a logistic regression analysis to choose CA125 and HE4 levels that are best fitted to predict chemoresponse. A total of 76 patients were divided into two groups: group A (n = 42) and group B (n = 34). After 6 months of follow-up, 40 patients were classified as platinum sensitive/intermediate and 36 as platinum resistant. At third chemotherapy cycle, in platinum-resistant patients, HE4 levels were >70 pmol/L in 36 of 36 cases, although in platinum-sensitive/intermediate patients, HE4 levels were >70 pmol/L only in six of 40 cases (sensitivity 100 %, specificity 85 %). Moreover, HE4 reduction of almost 47 % at third chemotherapy cycle reached the sensitivity of 83 % with a specificity of 87 % (positive predictive value = 0.86, negative predictive value = 0.85) in predicting chemoresponse. On the contrary, CA125 values during chemotherapy did not result statistically significant in predicting platinum response. Our findings suggest that HE4 values during first-line chemotherapy could predict chemotherapy response in EOC patients. |
Databáze: | OpenAIRE |
Externí odkaz: |